Cascades has reported improved third quarter sales driven by stronger volume, good operational execution, benefits from ongoing profitability initiatives, and favourable raw material and selling price trends.
Sales of $1,238m compared with $1,187m in Q2 2025 and $1,201m in Q3 2024, while operating income was $73m compared with $36m in Q2 2025 and $36m in Q3 2024.
EBITDA was $159m compared with $137m in Q2 2025 and $140m in Q3 2024.
Hugues Simon, President and Chief Executive, said: “Third quarter consolidated results exceeded our sequential forecast.
“This was driven by stronger volume, good operational execution, benefits from ongoing profitability initiatives, and favourable raw material and selling price trends.
“Our packaging business, in particular, had a stronger than expected quarter.
“This reflected continued positive volume momentum during the quarter, a well executed closure and redistribution of tonnage from the Niagara Falls mill, and a 24% increase in volumes produced at Bear Island, the latter of which achieved 90% of its targeted production ramp up curve in the quarter.
“As expected, our tissue business similarly had a strong quarter, driven by improvements in volume.”
Simon added the business was expecting fourth quarter performance to be stable sequentially on a consolidated basis.
“Notwithstanding favourable raw material and selling price trends and a continuation of good demand levels in October, we remain cautious in packaging,” he said.
“To this end, we are forecasting lower sequential results for this business, driven by our current expectation that volume will decrease in seasonally softer December.
“For tissue, we expect the momentum of sequentially stronger results to continue in the fourth quarter, driven by lower maintenance and favourable raw material costs.
“Looking further ahead, we are focused on achieving our strategic objectives.
“Despite the ongoing uncertainty in the current economic environment, we are making good progress across many of these initiatives.”
